As shown in Table 1, the prediction performances of ACAP1 were better than TIDE, MSI, TMB, and CD274 in >50% of melanoma cohorts and achieved a high prediction accuracy of ICT response with an AUC > 0.7, predicting a strong likelihood of positive response to immunotherapy, in four cohorts. This evidence concerns the gene ACAP1 and melanoma.